

Reference Number: FOI202223/459
From: Private Individual
Date: 12 December 2022
Subject: How many patients were treated in November 2022 (or latest available month) by the dermatology department with the following drugs

Q1 I am analysing the usage of new biologic medications within dermatology. Could you please tell me how many patients were treated in November 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.